Getinge recalled 98 units of the VASOVIEW HEMOPRO 3 Endoscopic Vessel Harvesting System on August 5, 2025. The recall addresses out-of-box failures including malfunctioning jaws and heater wires. No serious injuries were reported related to these failures.
On August 5, 2025, Getinge voluntarily initiated a Medical Device Removal for the Vasoview Hemopro 3 Endoscopic Vessel Harvesting System in response to reports of out-of-box failures discovered during the limited launch phase. There were sixteen complaints on the same date pertaining to specific failure modes, including angled deformity at the attachment site of the Harvesting Tool Jaws and the distal end of the Harvesting Tool Shaft, jaws not fully closed out of box, and heater wire lifted/flexed away from jaws. These sixteen complaints corresponded to sixteen total device malfunctions affecting devices that had not progressed to the pre-test step or clinical use. Notably, no serious injuries were reported in association with these device failures, as the non-conforming devices were identified during device inspection prior to patient exposure.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Maquet Cardiovascular, LLC or your healthcare provider for instructions. Notification method: Telephone
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled models include VH-6000, VH-6001, and VH-6010. These devices were distributed nationwide in the U.S., specifically in Florida, Illinois, Maryland, and Texas. The quantity recalled is 98 units.
Reports indicate out-of-box failures, including angled deformities at the jaw attachment site and non-closure of the jaws. Sixteen complaints detailed malfunction issues before the devices reached clinical use.
No serious injuries occurred. Sixteen complaints were reported regarding the malfunction of the devices.
Stop using the VASOVIEW HEMOPRO 3 immediately. Contact Maquet Cardiovascular, LLC for further instructions on the recall.
For more information, call Maquet Cardiovascular, LLC. Visit the recall notice at the FDA website for detailed instructions.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.